Screen your compounds across our comprehensive cell screening panel of over 600 authenticated, validated human cancer cell lines covering 50 cancer types.

The adaptor protein STING (stimulator of interferon genes) has emerged as an exciting target for both immunological conditions (STING inhibition) and cancer therapies (STING activation). Leverage our expertise now to accelerate your STING research!.

View our recent publication! WuXi AppTec scientists contributed to a study which led to the discovery and optimization of a novel series of GST inhibitors.

WuXi AppTec is proud to present five scientific posters at this year’s SITC meeting in San Diego, November 1 – 5. While you’re in San Diego, join our poster presentations, prearrange a dedicated meeting, and visit us at Booth 431! .

Join WuXi AppTec on October 31st when we showcase our integrated platform to support the discovery stages of a viral gene therapy program. Register by clicking here:

Join us at BIO Europe 2023! Come and visit us at Booth 95 or request a meeting with us via PartneringOne. We would love to see you there. #biotech #biotechnology #drugdiscovery #drugdevelopment #BIO23 #BIOEurope.

Join us in Boston for the 6th Annual Targeted Protein Degradation Summit! You will find us in the exhibit area, where our experts will be delighted to discuss your upcoming projects. Click below to prearrange a dedicated meeting.

Atopic dermatitis (AD) is the most common, chronic inflammatory skin disease. To support drug discovery research in this area, WuXi AppTec offers a broad platform of validated, in vivo AD models. Our panel includes DNCB, DNFB, and MC903-induced AD models.

WuXi AppTec offers Jurkat reporter cell lines for immunotherapy drug screening, which includes CD8+, TCR knockout and CD16-expressing Jurkat-NFAT-Luc reporter cell lines, validated assays to evaluate the activity of CARs, TCRs, and bispecific antibodies.

Cyclin-dependent kinase 2 (CDK2) and its respective cyclin E1 and cyclin A2 complexes are essential for driving abnormal growth processes in cancer cells, making these proteins important targets for cancer treatment.

The metabotropic glutamate receptor mGluR7 is widely expressed throughout the CNS and has been implicated in numerous CNS disorders.

Cell migration, invasion, and adhesion are pivotal steps in cancer metastasis. To support research in this field, WuXi AppTec offers in vitro transwell migration and invasion assays using multiple cell types for assessing cell migratory behavior.

Our expert speakers discuss the use of DNA encoded libraries (DEL) to discover peptide macrocycles that disrupt protein-protein interactions, and they provide a case study employing the oncoprotein murine double minute 2 (MDM2).

Protein arginine methyltransferase 5 (PRMT5) is an enzyme which plays an essential role in a wide range of cellular processes. PRMT5 overexpression has been implicated in many diseases, including cancer, making this protein an important drug target.

WuXi AppTec has launched DELman - our automatic DNA-encoded library (DEL) screening device. Researchers are making great strides using DEL technology to generate new molecules as starting points for their drug discovery projects.

In this webinar, our expert speakers discuss the use of DNA encoded libraries (DEL) to discover peptide macrocycles that disrupt protein-protein interactions, and they provide a case study employing the oncoprotein murine double minute 2 (MDM2).

Werner syndrome helicase (WRN) is a key drug target for cancers with microsatellite instability.

In our latest issue of OncoWuXi Express, we showcase the antitumor efficacy of an mRNA-encoded bispecific antibody (EpCAM/CD3) in PBMC humanized mouse models.

This week's #HowDoesItWork episode features Peptide-Oligonucleotide Conjugates. Peptide-oligonucleotide conjugates are made up of peptide and oligonucleotide components. These cutting-edge molecules have many applications in biomedicine. Subscribe here:

Read our latest White Paper on recent advances in the development of oligonucleotide-based therapeutics. Designing effective oligonucleotide therapeutics involves understanding both the chemistry and biology of nucleic acids.